Trials Sponsors Conditions Drugs Pricing

Conditions

COVID-19-Associated Thromboembolism

Keywords

COVID-19thromboembolismVariants of COVID-19

Outcome Measures

Primary Outcomes (1)

Rate of thromboembolic complications among patients who effected from different variants of COVID-19 Disease
Both arterial and venous thromboembolic events were detected
During the entire intensive care stay up to 1 day

Secondary Outcomes (3)

Rate of thromboembolic complications of COVID-19 disease in critically ill patients
During the entire intensive care stay up to 1 day
Rate of thromboembolic complications according to anticoagulant therapy
During the entire intensive care stay up to 1 day
What is the rate of thromboembolism according to the comorbidities
During the entire intensive care stay up to 1 day

Study Arms (4)

Ancestral variant

Ancestral variant is the first subtype of SARS CoV-2 virus which is the agent of first COVID-19 infection in Wuhan. Thromboembolic complications of this group were detected among patients which were infected with ancestral variant of COVID-19

Delta Variant

Delta variant is the subtype of SARS CoV-2 virus which is first COVID-19 subtype identified in India. Thromboembolic complications of this group were detected among patients which were infected with delta variant of COVID-19

Alpha variant

Alpha variant is the subtype of SARS CoV-2 virus which is first identified COVID-19 subtype in United Kingdom. Thromboembolic complications of this group were detected among patients which were infected with alpha variant of COVID-19

Other variants

Other variants is the subtype of SARS CoV-2 virus which were identified in Brazil, South Africa..etc. Thromboembolic complications of this group were detected among patients which were infected with alpha variant of COVID-19

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodProbability Sample

Study Population

Study Population of the present study is all of the patients diagnosed with COVID-19 and admitted to the intensive care units at Derince Training and Research Hospital at the time of between 1-March-2020 and 31-December-2021in

You may qualify if:

Patients who were infected with COVID-19 and admitted to the intensive care unit between the time of March 2020-December 2021

Sponsors & Collaborators

Ayse Zeynep Turan
Otherlead

Study Sites (1)

Derince Research and Training Hospital

Kocaeli, Derince, 41900, Turkey (Türkiye)

MeSH Terms

Conditions

COVID-19Thromboembolism

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract DiseasesEmbolism and ThrombosisVascular Diseases

Study Officials

Berna Karakoyun Lacin, Prof.
Health and Science University Hamidiye Institute of Health Sciences
PRINCIPAL INVESTIGATOR

Enrollment

484 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: RETROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR INVESTIGATOR
PI Title: Principle Investigator

Study Record Dates

First Submitted

September 1, 2023

First Posted

September 14, 2023

Study Start

January 1, 2022

Actual (reported)

Thromboembolic Complications in COVID-19 Patients in Intensive Care Unit

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (3)

Study Arms (4)

Ancestral variant

Delta Variant

Alpha variant

Other variants

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (3)

Study Arms (4)

Ancestral variant

Delta Variant

Alpha variant

Other variants

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations